EGFR and urinary bladder carcinoma: In reality, PPARγ agonist markedly sensitized bladder cancer cell lines, particularly those that were resistant to EGFR inhibition, in a schedule-specific manner, suggesting it can be an excellent alternative when cells are resistant to the aforementioned monotherapies.